/PRNewswire/ -- As a leading provider of medical solutions in the field of neurosurgery, ZEISS Medical Technology is also dedicated to shaping modern oncology. The company recently received 510(k) clearance from the US Food and Drug Administration (FDA) for

/PRNewswire/ -- 作为神经外科领域医疗解决方案的领先提供商，蔡司医疗技术公司同样致力于塑造现代肿瘤学。该公司最近获得了美国食品和药物管理局 (FDA) 的 510(k) 许可。

– a leading-edge platform that provides robotic-assisted precision to support intraoperative radiation therapy (IORT). With its modern digital-first architecture, ZEISS INTRABEAM 700 creates SMART workflow efficiency and provides seamless connectivity, offering real added value for neurooncology and breast cancer therapy..

ZEISS INTRABEAM 700 是一个前沿平台，为术中放射治疗 (IORT) 提供机器人辅助的精准支持。凭借其现代化的数字化优先架构，ZEISS INTRABEAM 700 创造了智能化的工作流程效率，并提供无缝连接，为神经肿瘤学和乳腺癌治疗带来真正的附加价值。

ZEISS INTRABEAM 700

蔡司 INTRABEAM 700

'Based on our established INTRABEAM platform, the newly developed ZEISS INTRABEAM

‘基于我们已建立的INTRABEAM平台，新开发的ZEISS INTRABEAM

the next major step on our path to shaping the oncology workflows of tomorrow,' says Dr.

“在我们塑造未来肿瘤学工作流程的道路上，这是下一个重要的步骤，”博士说。

Christian Schwedes

克里斯蒂安·施韦德斯

, Head of the Neuro- and Spine Surgery Business Sector at ZEISS Medical Technology. 'It is especially designed for a precise, structured and risk-adapted treatment of brain tumors. From smart robotic positioning of the system, a more efficient workflow before and during the application, to bringing the system into the 21.

蔡司医疗技术神经与脊柱外科业务部门负责人。“它特别设计用于精准、结构化和风险适应性的脑肿瘤治疗。从智能机器人系统的定位，到应用前和应用过程中的更高效工作流程，再到将系统带入21世纪。

century when it comes to digitalization and connectivity, the ZEISS INTRABEAM 700 will support the efficient and seamless collaboration between neurosurgery and oncological therapy.'

百年来在数字化和连接性方面，ZEISS INTRABEAM 700 将支持神经外科与肿瘤治疗之间的高效无缝协作。

Robotic-assisted Precision

机器人辅助精准性

In oncological treatments, it must be ensured that the target area is optimally resected, and that healthy tissue is spared as much as possible. Especially during contact irradiation, it is important that the target focus always remains the same throughout the entire treatment, without interruptions or unintended movements.

在肿瘤治疗中，必须确保目标区域得到最佳切除，并尽可能保护健康组织。特别是在接触放疗期间，重要的是目标焦点在整个治疗过程中始终保持不变，无中断或意外移动。

The cutting-edge maneuverability of the brand-new robotic .

全新机器人的前沿机动性。

ZEISS INTRABEAM SMART Stand

蔡司INTRABEAM SMART支架

meets these clinical requirements and offers excellent positioning control at every stage of the treatment.

满足这些临床需求，并在治疗的每个阶段提供卓越的定位控制。

ZEISS INTRABEAM SMART Stand supports the precise positioning of the applicator by allowing it to approach the cavity fast, but also to slow down the speed of movement when navigating the applicator within the cavity. Once the applicator is in place, the active damping and the stand dynamics reduce residual vibrations to a minimum..

ZEISS INTRABEAM SMART 支架通过使施用器能够快速接近腔体，同时在腔体内导航时减慢移动速度，从而支持施用器的精确定位。一旦施用器就位，主动阻尼和支架动态特性会将残余振动降至最低。

'The new incarnation of the INTRABEAM 700 really gives you more range of motion in the delivery of the applicator to the cavity. It gives you precision in how movements can be made inside of the resection cavity by the applicator,' says

“INTRABEAM 700 的新版本确实让你在将施用器输送到腔体时拥有更大的运动范围。它让你能够精确控制施用器在切除腔内如何进行移动，”

Christopher Cifarelli

克里斯托弗·奇法雷利

SMART Workflow Efficiency

智能工作流效率

To achieve the best patient outcomes, healthcare professionals would like to focus solely on the treatment. ZEISS INTRABEAM 700 offers Smart Workflow Efficiency based on a digital-first architecture:

为了实现最佳的患者治疗效果，医疗专业人员希望仅专注于治疗。ZEISS INTRABEAM 700 基于数字化优先架构，提供了智能工作流程效率：

The new sterile

新的无菌

ZEISS INTRABEAM SMART Spherical Applicators

蔡司 INTRABEAM SMART 球形施用器

come with digital-assisted applicator management and the related

配有数字辅助的应用器管理及相关的

ZEISS INTRABEAM Spherical Sizer Set

蔡司 INTRABEAM 球面测量仪套装

also eliminates the need for sterilization. The convenient and smart draping and balancing functions support clinical workflow efficiency further. With a single tap, all functions can be controlled with a modern and intuitive graphical user interface (GUI), familiar from other ZEISS devices.

还消除了对灭菌的需要。便捷且智能的覆盖和平衡功能进一步提升了临床工作流程效率。通过一次点击，所有功能都可以使用现代化且直观的图形用户界面 (GUI) 进行控制，这个界面在其他 ZEISS 设备中也很熟悉。

Furthermore, the completely redesigned Radiance™ treatment planning simulation software enables oncologists to assess and simulate all relevant intraoperative radiation dosage parameters based on individual patient data prior to treatment in a simpler and faster workflow, reducing unexpected treatment disruptions during surgery.

此外，全新设计的Radiance™治疗规划模拟软件使肿瘤医生能够根据患者的个体数据，在治疗前以更简单、更快速的工作流程评估和模拟所有相关的术中辐射剂量参数，减少手术过程中的意外治疗中断。

This is key to successful surgical oncology procedures, resulting in optimal patient outcomes..

这是成功进行外科肿瘤手术的关键，能够为患者带来最佳疗效。

Seamless Connectivity

无缝连接

As part of the digitalization megatrend, connectivity is also becoming increasingly important in surgical oncology workflows worldwide. ZEISS INTRABEAM 700 can be integrated seamlessly into the surgical infrastructure and the hospital information system. Direct access to leading digital solutions from ZEISS enables faster routine workflows and simplified data management.

作为数字化大趋势的一部分，互联性在世界范围内的外科肿瘤学工作流程中也变得越来越重要。ZEISS INTRABEAM 700 可以无缝集成到外科基础设施和医院信息系统中。直接访问来自蔡司的领先数字解决方案，能够加快日常的工作流程并简化数据管理。

The platform also provides integrated applicator recognition and confirmation through embedded Radio Frequency Identification (RFID) technology..

该平台还通过嵌入式射频识别 (RFID) 技术提供集成的应用器识别和确认功能。

For progress in medical technology

为了医疗技术的进步

The latest generation of the INTRABEAM platform highlights ZEISS' innovative strength and is an example of how the company is driving medical innovation in cancer therapy: INTRABEAM from ZEISS is currently already used in multiple large clinical studies to research intraoperative radiotherapy in brain tumors, and clinical data has already been published.

最新一代的INTRABEAM平台彰显了蔡司的创新能力，也是该公司如何推动癌症治疗领域医学创新的一个范例：蔡司的INTRABEAM目前已经在多个大型临床研究中用于探索脑肿瘤的术中放疗，并且已有临床数据发布。

In addition, work on new clinical and patient-related data in the field of breast cancer is ongoing.*.

此外，乳腺癌领域的新临床和患者相关数据的工作正在进行中。*

ZEISS will present its latest solution for intraoperative radiotherapy from

蔡司将展示其最新的术中放疗解决方案

April 25 to 28, 2025

2025年4月25日至28日

, at the American Association of Neurological Surgeons Annual Scientific Meeting (AANS) in

，在美国神经外科医师协会年度科学会议（AANS）上

INTRAMET – phase 2 study – Brain Metastases – publication expected in 2026; INTRAGO II – phase 3 study – Glioblastoma – completed in 2024 (publication expected for 2026); TARGIT-E – phase 3 study Breast cancer in elderly patients – publication expected in 2025; TARGIT-US – phase 4 study Breast cancer – publication expected in 2027..

INTRAMET – 第二阶段研究 – 脑转移 – 预计2026年发表；INTRAGO II – 第三阶段研究 – 胶质母细胞瘤 – 2024年完成（预计2026年发表）；TARGIT-E – 第三阶段研究 – 老年乳腺癌患者 – 预计2025年发表；TARGIT-US – 第四阶段研究 – 乳腺癌 – 预计2027年发表。

Carl Zeiss Meditec AG

卡尔蔡司医疗技术公司

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients.

卡尔蔡司医疗技术公司（Carl Zeiss Meditec AG，ISIN：DE0005313704），在德国证券交易所的MDAX和TecDAX上市，是全球领先的医疗技术公司之一。该公司提供创新技术和应用导向的解决方案，旨在帮助医生提高患者的生活质量。

The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September)..

公司提供包括植入物和耗材在内的完整解决方案，用于诊断和治疗眼科疾病。公司在显微外科领域创造创新的可视化解决方案。集团在全球拥有5,730名员工，在2023/24财年（截至9月30日）创造了20.661亿欧元的收入。